This study aimed to explore the efect of alpha keto acid combined with hybrid blood purification treatment in patients with maintenance hemodialysis (MHD). 106 patients with MHD were treated in our hospital from February 2017 to January 2020. They were divided into observation group (n=53) and control group (n=53) using a random number table. The control group was given heterozygous blood purification, and the observation group was given alpha keto acid combined with heterozygous blood purification for 6 months. Compared with the renal function indexes before treatment, the levels of SCr and BUN in the 2 groups decreased after 3 and 6 months of treatment, and the reduction in the observation group was higher; After 3 and 6 months of treatment, the levels of TP, PA and Alb in the observation group were higher than those in the control group; Compared with before treatment, after 3 months and 6 months of treatment, the mineral metabolism indexes such as iPTH, P, Ca×P and the levels of Sclerostin, BMP-7 and Irisin in the observation group were significantly improved. Serum levels of TNF-a, IL-6, and CRP in the observation group were lower than those in the control group after 3 and 6 months of treatment; Compared with the situation before treatment, KDTA scores in the two groups increased after 3 and 6 months of treatment, and the increase in the observation group was higher. The application of compound alpha keto acid tablets combined with hybrid blood purification therapy in MHD patients has a positive efect on improving renal function, nutritional status, and quality of life. It can efectively reduce the body's micro-inflammatory state, while regulating mineral metabolism and the expression of Sclerostin, BMP-7 and Irisin, and inhibiting vascular calcification.